Skip to main content
Delfa

← All trials/NCT05442450

OSO

UnknownPhase 4

Efficacy of Oral Semaglutide in Overweight or Obesity

Efficacy of Oral Semaglutide in Overweight or Obesity : Randomized Controlled Trial (OSO Study - Oral Semaglutide for Obesity)

Asset

Semaglutide

Oral · GLP-1 agonist

Listed sites

1

Recruiting sites

1

Estimated enrollment

116

Study population

Obesity / overweight

Eligibility highlights

-

Primary endpoint

•≥5% weight-loss responders

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05442450
Org study IDAIG/IEC-BH@R 27 /05.2022-03

Timeline

Milestones

Study first posted2022-07-05actual
Study start2022-07-10actual
Last update posted2022-07-20actual
Primary completion2023-06-30estimated
Study completion2023-06-30estimated

Assets

Investigational agents

Semaglutide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Consecutive consenting patients of both genders with either a BMI of 30 or greater or a BMI of 27 or greater with one or more treated or untreated weight-related coexisting conditions (i.e., prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).

Exclusion criteria

•• Diabetes mellitus
-A glycated haemoglobin level of 48 mmol per mole (6.5%) or greater,
-A history of chronic pancreatitis
-Acute pancreatitis within 180 days before enrolment
-Previous surgical obesity treatment
-Use of antiobesity medication within 90 days before enrolment
-Pregnancy and planning for pregnancy
-Known malignancy

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
5
Cardiometabolic biomarkers
2
Glycemic / diabetes
1

Weight & body composition

5 endpoints
Primary/protocol endpoint

The proportion of patients achieving a reduction in body weight of 5% or more from baseline

Time frame:seven months

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

The percentage change in body weight from baseline to week 28

Time frame:Week 0 to week 28

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Achievement of body weight reduction greater than or equal to 10% (Yes/No)

Time frame:From baseline (week 0) to end of treatment (week 28) ]

≥10% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Change in waist circumference

Time frame:baseline (week 0) to end of treatment (week 28)

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint

Change in body mass index (BMI)

Time frame:baseline (week 0) to end of treatment (week 28)

BMI, change

change from baseline, improvement

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Change in fasting serum insulin

Time frame:baseline (week 0) to end of treatment (week 28)

ratio, improvement

Cardiometabolic biomarkers

2 endpoints
Secondary/protocol endpoint

Change in systolic blood pressure

Time frame:baseline (week 0) to end of treatment (week 28)

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Change in diastolic blood pressure

Time frame:baseline (week 0) to end of treatment (week 28)

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.